Wake Forest is part of DAWN, a multinational study recruiting 13,000 Black, Hispanic and African participants to study genetic and biomarker drivers of Alzheimer’s disparities.

Raleigh recruiters say Copilot and chatbots speed resume-building and job matches — but career coaches warn the efficiencies are shrinking entry-level hiring. Surveys back up the gap between faster searches and fewer starter roles.

Levitate raised $16M and plans to hire more than 100 people in Raleigh as it scales its AI-powered relationship-marketing business. The company will also expand offices in Toronto and Wilmington.

NCCU has won a $10M NIH subgrant — part of a Duke-led award — to fund seven years of community-focused medical research, student training and faculty pilot projects. The money will support data dashboards, workforce training and community-engaged studies across 11 departments.

New national data show five‑year lung‑cancer survival has climbed to about 30 percent. Triangle doctors point to immunotherapy, testing and screening as key drivers.

A Duke‑led study in Forsyth County is testing drones that deliver AEDs to 911 cardiac‑arrest calls, lowering devices to bystanders while EMS heads to the scene.

United Therapeutics' Phase 3 ralinepag cut clinical worsening risk by 55% and the company says the drug could be a $2B rival to J&J's Uptravi.

A Triangle Business Journal ranking shows the region’s 25 biggest VC backers raised about $1.5B in 2025, highlighting concentrated capital and a life‑sciences tilt.

Duke researchers found that resident immune cells in the eye’s drainage tissues clear debris and help control pressure; removing them in mice raised intraocular pressure. The work, published in Immunity, points to a new target for glaucoma therapies.

Ralliant opened its global headquarters in Raleigh’s North Hills and kicked off a hiring push for up to 180 high‑paying corporate roles supported by state incentives.

A Carrboro mother and UNC researchers are testing an enzyme therapy that aims to slow brain decline in children with Hunter syndrome.

A UNC-developed closed-loop headset tuned brain rhythms and produced large symptom drops in a small pilot; researchers and company partners are planning randomized trials.

Raleigh startup Slate Medicines closed a $130M Series A to develop SLTE‑1009, an anti‑PACAP antibody for migraine prevention. The company plans a Phase 1 trial in mid‑2026.